Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

B-Cell Lymphomas: A European Perspective on Key Trials From ASH 2020

December 5-8, 2020; Virtual
Watch this focused video featuring an EU expert’s perspective on the clinical implications of key data on CLL and MCL from ASH 2020.
Lydia Scarfò, MD
Released: March 17, 2021

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Gilead Sciences, and Janssen.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for ex-US physicians and other healthcare professionals who care for patients with hematologic malignancies.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies.

Program Medium

This program has been made available online.

Related Content

Download these expert-selected slides from Clinical Care Options (CCO) on acute myeloid leukemia to help provide optimal treatment for your patients with AML.

Amir T. Fathi, MD Eunice S. Wang, MD Released: October 21, 2021

Shaji Kumar, MD, and Beth Faiman, PhD, share expert guidance on diagnosing and managing patients with AL and ATTR amyloidosis, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: October 21, 2021 Expired: October 20, 2022

Downloadable slideset on diagnosing and managing AL and ATTR amyloidosis, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Released: October 21, 2021

Prof. Paul Coppo shares his thoughts on the current management of aTTP using clinical guidelines, biomarkers, and targeted therapies, from Clinical Care Options (CCO)

person default Paul Coppo, MD, PhD Released: October 21, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue